[1] Patients should maintain realistic expectations and recognise that sustainable weight loss is a gradual process requiring commitment to both medication adherence and lifestyle changes
VESPER-1: the durability signal In a 32-week exploratory extension (Part B) of VESPER-1, Pfizer reports a 15.9% non-placebo-adjusted weight loss with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide in participants who escalated from placebo to active drug
, shellfish (oysters, scallops, mussels), and pine nut products are manufactured in the same manufacturing facility
Medicare Coverage for Wegovy (November 2025) Novo Nordisk announced a program offering Wegovy at $50/month for eligible Medicare beneficiaries
Dont waste another precious night tossing and turning
The independent reviewers flagged this same double edge, the way the same mechanism that heals can also feed tumors or drive damage, and Sikirics team had to write a defense against it